On October 2, 2020 Celex Oncology reported strong new data that confirms that its patent protected solution of combining a sodium channel blocker with a potassium channel opener produces an enhanced response in inhibiting metastatic invasion in cancer cells (Press release, CELEX Oncology, OCT 2, 2020, View Source [SID1234632186]). Today’s data also reinforces the Company’s earlier findings of inhibiting metastatic invasion by blocking voltagegated sodium channels.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s CEO and Professor Mustafa Djamgoz said "the new results are significant because they further underline and strengthen the potential of the new cancer treatment mechanism that we are developing in clinical trials".

The new data will make it possible to create a novel drug composition that will give the company’s drug candidates a prolonged patent life, and can benefit patients with a superior second-generation drug.

As reported earlier, the Celex mechanism appears to be present in in many (if not all) of the most commonly occurring cancer forms and as a result can offer a significant breakthrough in the treatment of major cancers. The Company’s CEO and Professor Mustafa Djamgoz adds "This means our treatment has the potential to benefit millions of patients around the world both as a stand-alone treatment or in combination with existing treatments." The Company expects this new development to have wide-ranging impact in clinical oncology.